Sarepta Therapeutics (SRPT) Restructuring Costs (2020 - 2026)

Sarepta Therapeutics has reported Restructuring Costs for 3 years, with the latest figure at $39.0 million in Q2 2026.

• On a quarterly basis, Restructuring Costs changed N/A year-over-year to $39.0 million in Q2 2026; TTM through Jun 2026 was $81.0 million, a 80.02% increase from a year earlier, with the FY2025 full-year figure at $42.0 million, changed N/A from the prior year.
• Restructuring Costs was $39.0 million for Q2 2026 at Sarepta Therapeutics, up from $1.5 million in the prior quarter.
• The five-year high for Restructuring Costs was $40.5 million in Q3 2025, with the low at $1.5 million in Q4 2025.